Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ce-245677. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ce-245677 SCHEMBL1940683 | 1.00 | PDGFRB (0.61) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5316388 | 0.97 | PDGFRB (0.58) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5458170 | 0.97 | PDGFRB (0.58) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5457086 | 0.92 | PDGFRB (0.55) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941041 | 0.92 | PDGFRB (0.60) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5428869 | 0.92 | PDGFRB (0.52) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL14339404 | 0.91 | PDGFRB (0.49) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941202 | 0.91 | PDGFRB (0.73) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL14339406 | 0.90 | PDGFRB (0.64) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941712 | 0.90 | PDGFRB (0.64) | PDGFRBNTRK2NTRK1NTRK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872282-B2 | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane | AMGEN INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-3434788-B1 | CLASSIFICATION AND ACTIONABILITY INDICES FOR LUNG CANCER | LIFE TECHNOLOGIES CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3430163-B1 | GENE SIGNATURES FOR CANCER DETECTION AND TREATMENT | ALMAC DIAGNOSTIC SERVICES LTD (GB) | 2022-10-19 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |